Full Year 2023 Investor Presentation

23 Investor presentation Full year 2023 Sales growth of 36%, driven by the GLP-1 portfolio for diabetes and obesity treatment Novo NordiskⓇ DKK billion 70 560 Reported sales CAGR1: 12.5% Novo Nordisk reported quarterly sales Reported sales for the full by therapy year 2023 Rare Other Reported sales and growth breakdown for the full year 2023 Therapy Sales (mDKK) Growth Share of growth 60 Rare endocrine rare blood disorders disease Injectable GLP-12 104,382 50% 56% RybelsusⓇ 18,750 71% 13% disorders 1% 50 Total GLP-1 123,132 52% 69% -5.1%1 5%2% Obesity Total insulin³ 48,022 -6% -4% 40 -1.7%1 care 18% Other Diabetes care4 2,312 -15% -1% 2.7%1 Total Diabetes care 173,466 29% 64% 30 20 Obesity care5 41,632 154% 41% 14.4 %1 20 Diabetes and Obesity care 215,098 42% 105% Rare blood disorders6 11,776 3% 0% 74% 10 0 Diabetes care Q4 Other rare disease 2013 Rare endocrine disorders Q4 2023 Rare endocrine disorders? Other Rare disease Rare disease Total 3,836 -47% -5% 1,551 -4% 0% 17,163 -15% -5% 232,261 36% 100% Rare blood disorders Diabetes and Obesity care Sales of DKK 232.26 billion (~36%) 1 CAGR for 10-year period; 2 Comprises Victoza®, Ozempic®; 3 Comprises Tresiba®, XultophyⓇ and Levemir®, RyzodegⓇ and NovoMix®,FiaspⓇ and Novo RapidⓇ: 4 Primarily NovonormⓇ, needles and Gluca Gen® HypoKitⓇ; 5 Comprises SaxendaⓇ and Wegovy®: 6 Comprises NovoSeven®, Novo Eight®, NovoThirteenⓇ Refixia®, and Esperoct®; 7 Comprises NorditropinⓇand Macrilen TM; 8 Primarily VagifemⓇ and ActivelleⓇ Note: Sales numbers are reported in Danish kroner; Growth is at constant exchange rate, except for total sales growth of 29%; Refixia® and NovoThirteenⓇ are launched as RebinynⓇ and TRETTENⓇ, respectively, in North America.

View entire presentation